Veru: Combo to Optimize Weight Loss by Preventing Muscle Wasting, Increasing Fat Loss in Phase 2b Study

 In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function --

-- Weight-loss drugs like Ozempic, Wegovy, Mounjaro and other GLP-1 drugs cause a significant loss of both fat and muscle; in older obese or overweight patients who may already have low muscle mass, the further drop in muscle mass of all-important muscles increases risk of muscle weakness, functional limitations, mobility disability, falls, higher hospitalizations, and greater mortality --

-- The Company plans to conduct a Phase 2b double-blind, placebo-controlled study to evaluate enobosarm and GLP-1 drug combination for weight loss to prevent muscle loss and to preferentially increase fat loss in patients who are overweight or have obesity --

-- Phase 2b clinical obesity study to be open for enrollment as early as calendar Q1 2024 --

https://www.globenewswire.com/news-release/2023/10/04/2754580/11676/en/Veru-Reports-Muscle-Data-from-5-Clinical-Studies-of-Enobosarm-that-Support-the-Advancement-of-Enobosarm-in-Combination-with-Weight-Loss-GLP-1-Drugs-Ozempic-Wegovy-or-Mounjaro-to-Op.html